Cellectar Biosciences Statistics Share Statistics Cellectar Biosciences has 3.19M
shares outstanding. The number of shares has increased by 0.03%
in one year.
Shares Outstanding 3.19M Shares Change (YoY) 0.03% Shares Change (QoQ) 0% Owned by Institutions (%) 11.3% Shares Floating 2.96M Failed to Deliver (FTD) Shares 929 FTD / Avg. Volume 0.6%
Short Selling Information The latest short interest is 94.42K, so 2.96% of the outstanding
shares have been sold short.
Short Interest 94.42K Short % of Shares Out 2.96% Short % of Float 2.96% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.31 and the forward
PE ratio is -0.58.
Cellectar Biosciences's PEG ratio is
0.01.
PE Ratio -0.31 Forward PE -0.58 PS Ratio 0 Forward PS 4.2 PB Ratio 0.96 P/FCF Ratio -0.29 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cellectar Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.58,
with a Debt / Equity ratio of 0.03.
Current Ratio 2.58 Quick Ratio 2.58 Debt / Equity 0.03 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-4.05M Employee Count 11 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 66K Effective Tax Rate -0.15%
Stock Price Statistics The stock price has increased by -92.03% in the
last 52 weeks. The beta is 0.51, so Cellectar Biosciences's
price volatility has been higher than the market average.
Beta 0.51 52-Week Price Change -92.03% 50-Day Moving Average 4.84 200-Day Moving Average 10.32 Relative Strength Index (RSI) 51.2 Average Volume (20 Days) 154,574
Income Statement
Revenue n/a Gross Profit n/a Operating Income -51.78M Net Income -44.58M EBITDA -51.49M EBIT -51.78M Earnings Per Share (EPS) -40.72
Full Income Statement Balance Sheet The company has 23.29M in cash and 494K in
debt, giving a net cash position of 22.79M.
Cash & Cash Equivalents 23.29M Total Debt 494K Net Cash 22.79M Retained Earnings -247.34M Total Assets 13.7M Working Capital 6.75M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -47.58M
and capital expenditures -104.19K, giving a free cash flow of -47.69M.
Operating Cash Flow -47.58M Capital Expenditures -104.19K Free Cash Flow -47.69M FCF Per Share -31.05
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CLRB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CLRB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 24, 2025. It was a
backward
split with a ratio of 1:30.
Last Split Date Jun 24, 2025 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -33.66 Piotroski F-Score 1
